Saturday - March 28, 2026

Category Archives: Pharmaceuticals & Biotech

Philips Respironics Simply Go Mini Portable Oxygen Concentrator Redefines Mobility and Freedom for Active Oxygen Therapy Users Worldwide

The global demand for portable oxygen solutions continues to rise as more patients seek independence, mobility, and improved quality of life. In response to this growing need, the Simply Go Mini 手提氧氣機 has emerged as a leading innovation, combining advanced … Continue reading →

TIGIT Inhibitor Clinical Pipeline Strengthens as 14+ Companies Advance 18+ Novel Immunotherapy Candidates | DelveInsight

TIGIT Inhibitor Clinical Trial TIGIT Inhibitor Companies include Genentech, BeiGene, Arcus Biosciences, iTeos Therapeutics, Merck KGaA, Curocell, Agenus, Compugen, Tasrif Pharmaceutical, Y-Biologics, Aurigene, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, and others. DelveInsight’s latest report, “TIGIT Inhibitor Pipeline Insight 2026,” provides … Continue reading →

Pancreatic Cancer Treatment Pipeline Shows Strong Momentum as 170+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Pancreatic Cancer Pipeline Insight 2026” report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in Pthe ancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Thyroid Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 45+ Key Companies | DelveInsight

DelveInsight’s, “Thyroid Cancer Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

TGFB Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook

DelveInsight’s, “Transforming Growth Factor Beta Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Transforming Growth Factor Beta Inhibitors pipeline landscape. It covers the Transforming Growth Factor Beta Inhibitors pipeline drug profiles, including … Continue reading →

Ovarian Cancer Clinical Trial Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Ovarian Cancer Pipeline Insights 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Ovarian Cancer pipeline landscape. It covers the Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

PD-1 and PD-L1 Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook

DelveInsight’s “PD-1 and PD-L1 Inhibitors Competitive landscape 2026” report provides comprehensive insights about 180+ companies and 200+ drugs in the PD-1 and PD-L1 Inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule … Continue reading →

Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, ROA, Molecules, Companies and Future Outlook

DelveInsight’s, “Checkpoint Inhibitors Competitive landscape 2026” report provides comprehensive insights about 50+ companies and 60+ drugs in Checkpoint Inhibitors Competitive landscape. It covers the Checkpoint Inhibitors Therapeutics assessment by product type, stage, route of administration, and molecule type. It further … Continue reading →

CDK 12 Inhibitor Clinical Trial Pipeline Accelerates as 3+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “CDK12 Pipeline Insight 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in CDK12 pipeline landscape. It covers the CDK12 Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CDK12 Pipeline Therapeutics … Continue reading →